Fluoroscopic Guided Interlaminar Epidural Versus Ultrasound Guided Transforaminal Epidural in the Treatment of Unilateral Cervicobrachialgia : a Randomized Controlled Trial

Trial Information
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable

Chronic cervicobrachialgia is a public health problem. Epidural injections of corticosteroids and local anesthesics via transforaminal and interlaminar routes both have shown their potential in its treatment. The interlaminar approach offers the advantage of an epidural injection (i.e., direct contact with the nerve root in the epidural space). However, it requires fluoroscopy and can lead to potentially serious complications (compression of the nerve root, spinal cord injury...). The ultrasound-guided injection of corticosteroids via the transforaminal route, which offers the advantage of selectively targeting the symptomatic nerve root, may have the same therapeutic advantages as the interlaminar approach in decreasing unilateral cervicobrachial pain (i.e. a decrease in pain after infiltration) and reduce its risks.The aim of this study is to compare the efficacy of transforaminal vs interlaminar cervical corticosteroid injection.

Am I eligible for this trial?
Participation Requirements
Minimum Age:
Healthy Volunteers:

• American Society of Anesthesiologists physical status (ASA) I-III

• Chronic unilateral cervicobrachial pain

• Allowed Steroid infiltration

Where is this trial taking place?
Other Locations
CHU Saint-Pierre
Who do I contact about this trial?
Panayota Kapessidou, MD,PhD
Mohamed Ali Bali, MD
+ 32.2.535
When is this trial taking place?
Start Date: July 30, 2020
Estimated Completion Date: July 2021
How many participants will be in this trial?
Target number of participants: 60
What treatment is being studied in this trial?
Experimental: Ultrasound guided transforaminal epidural steroid injection
Experimental: Interlaminar epidural steroid injection
Who are the authors of this trial?
Mohamed Bali, Mohamed Ali Bali

This content was sourced from clinicaltrials.gov